skip to content
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Yesterday a FDA official gave very negative opinions and comments on Aurinia pharmaceuticals then removed them at end of trading day. Volume went up to almost 8million shares and stock was crushed. This stinks to high heaven. What do you folks think of this and will there be law suits maybe officials checking into short covering etc. Also how long will the cloud remain over this stock it was just taking off when all this happened.
Read Answer Asked by Mark on October 01, 2025
Q: This stock is up 50% in less than a month and is at a 52 week high it also will be making about 270 million going forward this year. They get to keep 90% of that. My simple math has them at a P/E of 6.4 on a forward basis if they don’t overachieve. There drug is getting traction into the hospitals and with the doctors due to its drug profile.

Aurina has another drug in the pipeline going into phase two that looks good and I hope they go after rheumatoid arthritis. To me everything looks good here. This is my fun stock to stop me from becoming too bored and is finally becoming exciting.

What do you folks think is going on here regarding the big move in the stock price and where it could go. Looks like the existing drug revenue tops out an around 600 million annually.
Read Answer Asked by Mark on August 19, 2025
Q: Hey everyone, this 1b dollar company looks amazing to me. What am I missing? They have over 300 million in cash and are cash flow positive. This type of drug has been acknowledged recently as part of a drug regime that helps people with lupus nephritis its a calcinurin inhibitor.

How would you value this company? the market doesn’t like it even though it’s making 260million a year going forward with no debt. Is there an issue with the IP?
Read Answer Asked by Mark on May 20, 2025
Insiders
Share Information
SEC Filings
News and Media